Picture [iito] Made Without Love 650x80px
Document › Details

Orchard Therapeutics Ltd.. (3/6/18). "Press Release: Orchard Therapeutics to Present at the Cowen and Company Annual Healthcare Conference". London.

Region Region Boston, MA
  Country United States (USA)
Organisations Organisation Orchard Therapeutics Ltd.
  Group Orchard Therapeutics (Group)
  Organisation 2 Cowen & Company LLC
  Group Cowen (Group)
Products Product Cowen & Co. Annual Health Care Conference 2018 Boston
  Product 2 gene therapy
Index terms Index term Orchard Therapeutics–Cowen: investor conference, 201803 supply service Orchard presents at Cowen & Co Annual Health Care Conference 2018
  Index term 2 Orchard Therapeutics–LifeSci: public relations, 201712 service existent by LifeSci Public Relations
Persons Person Rothera, Mark (Orchard Therapeutics 201708– CEO before PTC Therapeutics + Aegerion + Shire Human Genetic Therapies)
  Person 2 Blum, Allison (LifeSci Public Relations 201712)

Orchard Therapeutics, a clinical-stage biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced that Mark Rothera, president and chief executive officer, will present at the Cowen & Co. 38th Annual Healthcare Conference on Wednesday, March 14, 2018, at 11:30 a.m. ET in Boston.

About Orchard Therapeutics

Orchard Therapeutics is a privately held clinical-stage biotechnology company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies. Orchard, based in the UK and US, has partnered with world leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital. Orchard’s growing pipeline of autologous ex vivo lentiviral gene therapy programs for rare immune deficiencies and metabolic disorders includes late clinical stage programs that have already demonstrated the transformative power of gene therapy on patients’ lives. In 2016 the company was named a Fierce 15 Company by Fierce Biotech and was awarded a $19 million grant from the California Institute of Regenerative Medicine (CIRM) to advance their autologous ex vivo lentiviral gene therapy in ADA-SCID. In 2017, Orchard raised $110 million in a Series B round of funding to further develop its pipeline in parallel with enhancing manufacturing capabilities.


Corporate contact
Nicolas Koebel
Orchard Therapeutics
+44 (0) 203 384 6700

Media contact
Allison Blum, Ph.D.
LifeSci Public Relations
+1 516 655 0842

Record changed: 2018-05-07


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Orchard Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Back into Ad 650x80px

» top